These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8720977)

  • 21. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of proliferation, estradiol receptors and estrogen regulated protein PS2/BCEI in human breast cancer cell lines by gamma interferon.
    Solary E; Prud'homme JF; Gauville C; Magdelenat H; Calvo F
    J Biol Regul Homeost Agents; 1991; 5(3):98-106. PubMed ID: 1763658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells.
    Stack G; Kumar V; Green S; Ponglikitmongkol M; Berry M; Rio MC; Nunez AM; Roberts M; Koehl C; Bellocq P
    Cancer Treat Res; 1988; 40():185-206. PubMed ID: 2908650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of pS2 estrogen-inducible protein in primary breast cancer.
    Horiguchi J; Iino Y; Takei H
    Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer.
    Fulco RA; Petix M; Salimbeni V; Torre EA
    Minerva Med; 1998; 89(1-2):5-10. PubMed ID: 9561019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of pS2 mRNA in breast cancer.
    Wysocki SJ; Iacopetta BJ; Ingram DM
    Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
    Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
    Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PS2 expression in BRCA1-associated breast cancers.
    Charafe-Jauffre E; Eisinger F; Mathoulin-Portier MP; Sobol H; Jacquemier J
    Anticancer Res; 2001; 21(4B):2877-81. PubMed ID: 11712780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
    Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
    Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma.
    Welter C; Theisinger B; Seitz G; Tomasetto C; Rio MC; Chambon P; Blin N
    Lab Invest; 1992 Feb; 66(2):187-92. PubMed ID: 1735955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
    van Agthoven T; van Agthoven TL; Dekker A; Foekens JA; Dorssers LC
    Mol Endocrinol; 1994 Nov; 8(11):1474-83. PubMed ID: 7533260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival.
    Müller W; Borchard F
    J Pathol; 1993 Dec; 171(4):263-9. PubMed ID: 8158455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.
    Yamakawa T; Morimoto T; Sasa M; Numoto S; Monden Y
    Jpn J Cancer Res; 1995 Nov; 86(11):1035-40. PubMed ID: 8567393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of the breast cancer-associated protein pS2 in adenosquamous carcinomas of the gastrointestinal tract.
    Welter C; Seitz G; Blin N
    Acta Oncol; 1993; 32(3):315-7. PubMed ID: 8323770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
    Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Estrogen receptor studies in breast cancer based on histological material. Correlation with results from needle biopsy aspirates and pS2 protein determination].
    Sauer T; Naess O
    Tidsskr Nor Laegeforen; 1995 Sep; 115(23):2881-3. PubMed ID: 7570508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
    Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
    Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective analysis of prognostic significance of the estrogen-inducible pS2 gene in male breast carcinoma.
    Kardaś I; Seitz G; Limon J; Niezabitowski A; Ryś J; Theisinger B; Welter C; Blin N
    Cancer; 1993 Sep; 72(5):1652-6. PubMed ID: 8394203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical parameters for prognostic evaluation in patients with breast cancer.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
    Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.